# Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma

> **NCT04712864** · PHASE1 · UNKNOWN · sponsor: **Legend Biotech USA Inc** · enrollment: 50 (estimated)

## Conditions studied

- T-Cell Lymphoma
- Peripheral T-Cell Lymphoma Refractory
- Cutaneous T-Cell Lymphoma Refractory
- Cutaneous T-Cell Lymphoma Recurrent
- Peripheral T-Cell Lymphoma Recurrent

## Interventions

- **BIOLOGICAL:** LB1901

## Key facts

- **NCT ID:** NCT04712864
- **Lead sponsor:** Legend Biotech USA Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-09-13
- **Primary completion:** 2023-12
- **Final completion:** 2025-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04712864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04712864, "Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04712864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*